Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453440 | 0.89 | GAA (0.44) | SMN1; SMN2POLBTP53MAPTALDH1A1 | |
| SCHEMBL5456020 | 0.82 | MAPT (0.41) | SMN1; SMN2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL5449196 | 0.82 | ABL1 (0.50) | MAPT | |
| SCHEMBL5460935 | 0.81 | MAPT (0.42) | POLBMAPTMEN1KMT2AHTT | |
| SCHEMBL5451020 | 0.81 | ABL1 (0.49) | SMN1; SMN2POLBTP53MAPTALDH1A1 | |
| SCHEMBL5453194 | 0.81 | ALDH1A1 (0.41) | POLBMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5451194 | 0.80 | POLB (0.40) | POLBTP53MAPTALDH1A1HPGD | |
| SCHEMBL5453479 | 0.79 | TNIK (0.37) | MAPTALDH1A1RECQLMEN1KMT2A | |
| SCHEMBL5454161 | 0.79 | FLT3 (0.41) | TP53MAPTHTT | |
| SCHEMBL5451669 | 0.78 | ESR1 (0.51) | TP53MAPTALDH1A1RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FKBP1A 777/4885SMN1; SMN2 2157/4885POLB 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.